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Abstract
Background: Visual field testing is an essential part of glaucoma care. It is hampered by variability related to the disease
itself, response errors and fatigue. In glaucoma, blind parts of the visual field contribute to the diagnosis but - once
established – not to progression detection; they only increase testing time. The aims of this study were to describe the
persistence and spatial distribution of blind test locations in standard automated perimetry in glaucoma and to explore how
the omission of presumed blind test locations would affect progression detection.
Methodology/Principal Findings: Data from 221 eyes of 221 patients from a cohort study with the Humphrey Field
Analyzer with 30–2 grid were used. Patients were stratified according to baseline mean deviation (MD) in six strata of 5 dB
width each. For one, two, three and four consecutive ,0 dB sensitivities in the same test location in a series of baseline
tests, the median probabilities to observe,0 dB again in the concerning test location in a follow-up test were 76, 86, 88 and
90%, respectively. For ,10 dB, the probabilities were 88, 95, 97 and 98%, respectively. Median (interquartile range)
percentages of test locations with three consecutive ,0 dB sensitivities were 0(0–0), 0(0–2), 4(0–9), 17(8–27), 27(20–40) and
60(50–70)% for the six MD strata. Similar percentages were found for a subset of test locations within 10 degree eccentricity
(P.0.1 for all strata). Omitting test locations with three consecutive ,0 dB sensitivities at baseline did not affect the
performance of the MD-based Nonparametric Progression Analysis progression detection algorithm.
Conclusions/Significance: Test locations that have been shown to be reproducibly blind tend to display a reasonable
blindness persistence and do no longer contribute to progression detection. There is no clinically useful universal MD cut-
off value beyond which testing can be limited to 10 degree eccentricity.
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Introduction
Glaucoma is a progressive disease that may cause irreversible
blindness. Monitoring of the disease with perimetry is an essential
part of glaucoma care, unless patients have a short life expectancy
and little glaucomatous damage. Variability hampers the use of
perimetry in detecting small changes in visual function. In
glaucoma, variability is presumably related to response errors,
fatigue effects [1,2] and a flatter frequency-of-seeing curve in
regions with a reduced sensitivity [3,4]. The development of the
Swedish Interactive Threshold Algorithm (SITA) strategies for the
Humphrey Field Analyzer (HFA) has partially resolved the fatigue
issue by reducing the test time [5].
SITA reduces the test time, amongst others, by predicting the
sensitivity in a test location from the sensitivity in neighboring test
locations and by incorporating general knowledge on glaucoma-
tous visual field patterns. However, SITA ignores an obvious other
source of prior knowledge, being the previous test result. The use
of the previous test result can reduce test time [6,7] and test-retest
variability [8]. To illustrate this, for a typical glaucomatous visual
field, that is, a blind superior hemifield together with an intact
inferior hemifield, the test time of SITA is about 1.5 times longer
than for a normal field. Hence, to establish blindness in a test
location takes twice as long as establishing a normal sensitivity –
and thus a 33% test-time reduction should be possible by
incorporating information from previous tests. This is in agree-
ment with earlier findings [7]. To go one step further, if the
superior hemifield would have been unresponsive on several
consecutive occasions, it makes no sense to test it again: only the
inferior hemifield needs to be tested to monitor the eye. Hence, a
67% test-time reduction would ultimately be possible in this case.
The aims of this study were (1) to describe the persistence and
spatial distribution of blind test locations in standard automated
perimetry in glaucoma and (2) to explore how the omission of
presumed blind test locations would affect progression detection.
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For the first aim, we determined the probability to observe a
sensitivity below a certain value as a function of the number of
preceding consecutive sensitivities below that value in the
concerning test location. This was evaluated for ,0, ,5, ,10
and ,20 dB. The value ,0 dB corresponds to the maximum
stimulus intensity of the HFA perimeter; the values ,5 and ,10
dB approximately to the maximum stimulus intensities of the
Octopus and Oculus perimeters, respectively. Subsequently, we
compared the percentages of blind test locations between the
regular standard automated perimetry 30–2 grid (with test
locations up to 30 degree eccentricity) and the subset of test
locations falling within the 10–2 grid (up to 10 degree eccentricity),
as a function of disease stage as defined by the mean deviation
(MD). The aim here was to determine a clinically useful MD cut-
off value for preferring 10–2 testing over 30–2 testing in advanced
glaucoma. After all, although glaucoma sometimes starts close to
fixation [9,10], it is conceptually a disease affecting the peripheral
visual field first and thus a transition from 30–2 to 10–2 testing
would be the easiest way to avoid uninformative testing of
unresponsive parts of the visual field in advanced disease. For the
second aim, we studied the performance of an MD-based
progression detection algorithm with and without assuming blind
test locations as established at baseline to be blind in all follow-up
fields.
Methods
Ethics Statement
The study protocol was approved by the ethics board of the
University Medical Center Groningen. This board approved
that for the current study no informed consent had to be
obtained because the study comprised a retrospective anony-
mous analysis of visual field data collected during regular
glaucoma care. To ensure a proper glaucoma diagnosis of the
included patients, we limited the study population of this study
to glaucoma patients that had been included in the Groningen
Longitudinal Glaucoma Study (GLGS) in the past. In the
GLGS, all glaucoma patients and glaucoma suspects who visited
the glaucoma outpatient service of the University Medical
Center Groningen between July 1, 2000, and June 30, 2001,
and who provided informed consent were included in an
observational study with conventional perimetry, frequency-
Table 1. Example of two patients as represented in the database, with two and eight test locations with a sensitivity of ,0 dB in
the fourth visual field, respectively.
Patient
VF1
(dB)
VF2
(dB)
VF3
(dB)
VF4
(dB)
VF5
(dB)
VF6
(dB)
VF7
(dB)
VF8
(dB) Position on VF % ,0 dB Mean (dB)
1 4 4 6 ,0 0 0 0 11 4 0 2.75
1 ,0 ,0 ,0 ,0 ,0 2 ,0 18 9 50 4.00
2 12 3 11 ,0 ,0 ,0 13 10 1 50 4.75
2 20 0 5 ,0 ,0 ,0 9 0 2 50 1.25
2 ,0 ,0 ,0 ,0 ,0 3 ,0 ,0 19 75 20.75
2 15 12 ,0 ,0 11 ,0 ,0 4 20 50 2.75
2 20 2 ,0 ,0 ,0 1 ,0 ,0 30 75 21.25
2 21 ,0 6 ,0 16 ,0 ,0 4 31 50 4.00
2 26 12 4 ,0 10 4 5 0 33 0 4.75
2 ,0 3 ,0 ,0 ,0 10 ,0 ,0 35 75 1.00
VF = visual field; columns VF1-VF4 refer to baseline, VF5-VF8 to follow-up; last two columns depict the data analysis as applied to the follow-up data (for details see
text).
doi:10.1371/journal.pone.0041211.t001
Table 2. Patient characteristics for all included 221 eyes of 221 patients and for the subset of 53 eyes of 53 patients with at least
eight visual field tests and at least one test location showing a ,0 dB sensitivity on four consecutive baseline tests (mean with
standard deviation between brackets unless stated otherwise).
N=221 N=53
Baseline
Age (years) 65.1 (12.3) 65.1 (10.3)
Gender (% male) 55.2 45.3
Right eye (%) 50.7 52.8
Mean Deviation (median [interquartile range]; dB) 27.0 (214.5 to 23.0) 214.7 (218.7 to 210.9)
Follow-up
Follow-up duration (years) 6.4 (1.2) 6.9 (1.0)
Rate of progression (median [interquartile range]; dB/year) 20.1 (20.5 to +0.1) 20.2 (20.5 to 0.0)
Square root of the residual mean square of Mean Deviation (dB) 1.1 (0.7) 1.2 (0.7)
doi:10.1371/journal.pone.0041211.t002
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Figure 1. Percentage of follow-up sensitivities being ,0, ,5, ,10 and ,20 dB as a function of the number of consecutive ,0, ,5,
,10 and ,20 dB baseline sensitivities. Boxplots show median, interquartile range, and 5th, 10th, 90th and 95th percentiles.
doi:10.1371/journal.pone.0041211.g001
Figure 2. Mean sensitivity during follow-up in test locations with 1, 2, 3 and 4 consecutive ,0, ,5, ,10 and ,20 dB baseline
sensitivities. Boxplots show median, interquartile range, and 5th, 10th, 90th and 95th percentiles.
doi:10.1371/journal.pone.0041211.g002
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doubling perimetry (FDT; Carl Zeiss Meditec AG, Jena,
Germany) and laser polarimetry (GDx; Laser Diagnostic
Technologies, San Diego, California, USA). Patients received
written information at home at least two weeks before their
regular care visit that was flagged as the baseline visit of the
study. The receipt of the information and agreement to
participate was checked verbally during the concerning visit.
The aim of the study was explained; participation was voluntary
and participation could be stopped also after having agreed to
participate. The study essentially comprised the collection of
regular care data obtained during regular visits and an
additional FDT and GDx test embedded in a regular visit.
FDT and GDx are non-invasive diagnostic tests with a very
limited additional burden and no additional risk for the patient.
The protocol of the original GLGS was approved by the
department of Medical Technology Assessment of the University
of Groningen. The original health technology assessment
research question was if it was possible to replace, in glaucoma
patients and/or glaucoma suspects, the lengthy and cumber-
some conventional perimetry by FDT and/or GDx. The study
followed the tenets of the Declaration of Helsinki.
Study Population
Details of the GLGS have been described earlier [11,12]. In
short, after the initial health technology assessment study described
above, we continued performing conventional perimetry in
glaucoma patients and moved to FDT/GDx in glaucoma suspects
in our regular care. The GLGS continued as an ongoing
anonymous gathering of all information from glaucoma patients
and glaucoma suspects obtained during regular care. For the
present study, we used data from a subpopulation of the GLGS
cohort: patients had to have (1) glaucoma at baseline (for criteria
see below) and (2) at least four (five with discarded learning test)
standard automated perimetry tests (HFA; Carl Zeiss Meditec
Inc., Dublin, CA).
Perimetry
Perimetry was performed using the HFA 30–2 SITA fast
strategy. For glaucoma, two consecutive, reliable tests had to have
defects according to previously published criteria [11,12]. For
being reproducible, defects had to be in the same hemifield and at
least one depressed test point of these defects had to have exactly
the same location on both tests. Moreover, defects had to be
compatible with glaucoma and without any other explanation (for
example, cataract, macular degeneration or lesions of the central
visual pathways). Prior to these two tests, another test had to be
made and this test was excluded to reduce the influence of
learning. During the follow-up period, perimetry was performed at
a frequency of one test per year. In case of suspected progression
or unreliable test results, clinicians could increase the frequency of
testing. This was a subjective decision; no formal tools or rules
were given (observational study design).
Data analysis
One eye per patient was included. If both eyes met the above-
described criteria, one eye was chosen randomly. For anatomical
representation, all left-eye threshold data were converted to a
right-eye format. Thresholds representing the blind-spot were
excluded from the analysis, leaving 74 tests locations for analysis.
Persistence of blindness. For this analysis we only included
patients who (1) performed at least eight tests and (2) had at least
one test location showing a ,0 dB sensitivity on four consecutive
baseline tests (most stringent criterion for blindness). We defined
four subgroups of test locations, based on the first four tests and
named VF4,0, VF3-4,0, VF2-4,0 and VF1-4,0. A test
location VF4,0 had to have a sensitivity of ,0 dB in the fourth
visual field test. A test location VF3-4,0 had to have a sensitivity
of ,0 dB in both the third and the fourth test, and so on. For
VF4,0, the sensitivity of the test location in the third test may or
may not be,0 dB. Hence, VF3-4,0 is a subset of VF4,0, and so
on. We took the fourth test as a reference in order to be able to
vary the number of baseline tests without the need of changing the
selection of the four follow-up tests, which were the fifth to eighth
test.
For all test locations with a sensitivity of ,0 dB in the fourth
test, we analyzed the corresponding sensitivities in the four follow-
up tests. Outcome measures were (1) the percentage of follow-up
tests showing a sensitivity of ,0 dB and (2) the mean sensitivity.
Here, test locations with ,0 dB were set at -2 dB. This is the
arbitrary interpretation of ,0 dB as chosen by the manufacturer.
For patients, the difference between 0 dB and ,0 dB implies
seeing the maximum light stimulus of the perimeter (0 dB) or not
(,0 dB).
Test locations within a single subject cannot be considered
independent. Therefore, to avoid that a few patients with many
blind test locations would dominate the results, we first determined
the averages and corresponding standard deviations of the
outcome measures within each patient for each subgroup of test
locations (VF4,0, VF3-4,0, VF2-4,0 and VF1-4,0). Subse-
quently, the averages were presented using nonparametric
descriptive statistics and the standard deviations of the first
outcome measure were averaged over all patients and presented as
the ‘‘mean within-patient standard deviation’’.
Table 1 gives an example of two patients as represented in the
database. These patients are present in the VF4,0 subgroup with
two and eight test locations, respectively. The first patient is also
present in the VF3-4,0, VF2-4,0 and VF1-4,0 subgroups, with
one test location. The second patient is present in these subgroups
with four, one and one test locations, respectively. For the first
patient, blindness persistence was 25% for the VF4,0 subgroup
and 50% for the VF3-4,0, VF2-4,0 and VF1-4,0 subgroups.
For the second patient, this was 53, 69, 75 and 75% for the
VF4,0, VF3-4,0, VF2-4,0 and VF1-4,0 subgroups, respec-
tively.
The analyzes were repeated with blindness of a test location
defined as a sensitivity of ,5, ,10 and ,20 dB instead of ,0 dB.
The influence of the number of consecutive tests (1, 2, 3 or 4)
showing blindness in a test location and the definition of blindness
(,0, ,5, ,10 or ,20 dB) on the persistence of blindness was
analyzed with ANOVA, with the persistence of blindness (average
Table 3. Analysis of variance with the number of consecutive
tests showing blindness in a test location (N) and the
definition of ‘perimetrically blind’ (B) as within-subject factors
and the persistence of blindness as dependent variable.
df MS dfe MSe F P
mean 1 680.65 52 0.08460 8045 ,0.001
N 3 0.47354 156 0.00702 67 ,0.001
B 3 0.57498 156 0.01089 53 ,0.001
N*B 9 0.00547 468 0.00161 3 ,0.001
df = degrees of freedom; MS=mean squares (MS= SS/df with SS = sum of
squares); dfe is df for error; MSe =mean squares for error.
doi:10.1371/journal.pone.0041211.t003
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percentage of follow-up tests showing blindness in the concerning
test locations) as the dependent variable.
Spatial distribution of perimetrically blind test
locations. For this analysis, we included all patients who
performed at least four tests. Patients were stratified according to
baseline MD in six strata, being above -5 dB, from -5 to -10 dB, -
10 to -15 dB, -15 to -20 dB, -20 to -25 dB en beyond -25 dB. We
plotted the test locations considered blind based on their sensitivity
history and calculated the percentages of these test locations, for all
test locations of the 30-2 grid and for a subset laying within the 10-
2 area. Percentages were compared with a nonparametric paired
test (Wilcoxon).
A commonly used progression detection algorithm, the Glau-
coma Progression Analysis (GPA) [13], has its own built-in
criterion for blindness: a cross on the printout indicates that the
test location is ‘out of range’ and not used for progression detection
by the software. We compared – for all six MD strata - the spatial
distributions and percentages of test locations flagged as ‘out of
range’ by GPA with that of test locations considered blind based
on their sensitivity history. Percentages were compared using a
nonparametric paired test (Wilcoxon).
Influence of assuming blindness on progression
detection. If the sensitivity of a test location has been below a
certain value on a number of consecutive tests, it might be an
efficient approach to consider such a test location blind in all
future tests – in glaucoma – without actually retesting it. This
might result in a (slight) underestimation of the MD and thus
might affect MD-based progression detection algorithms. To
determine the influence of this approach on clinical decision
making, we classified all included eyes as stable or progressing
according to the MD-based Non-parametric Progression Analysis
algorithm (NPA), with progression defined as at least possible
progression at the end of the follow-up (NPA is based on a
nonparametric ranking of MD values; for possible progression, the
MDs of the last two tests have to be lower than the lower MD of
two baseline tests) [12]. Subsequently, we repeated this after
assuming test locations to be perimetrically blind based on their
sensitivity history. Here, we excluded test locations from the
Figure 3. Spatial distributions of test locations that met various criteria for blindness, as a function of baseline mean deviation
(MD). The criteria were three consecutive sensitivities of ,0 (A), ,10 (B) and ,20 (C) dB, and being ‘out of range’ according to the Glaucoma
Progression Analysis (GPA; D). Black squares are the blind spot; white squares are test locations flagged as blind in 0–10% of the patients. The
remaining intermediate four gray scales denote, from light to dark, blindness in 10–20%, 20–40%, 40–60% and above 60% of the patients.
doi:10.1371/journal.pone.0041211.g003
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analysis if they were blind on the first three tests, according to four
different definitions of blindness: ,0, ,5, ,10 and ,20 dB. For
all four definitions, both classifications were compared with a
McNemar test. Because the MD is an average weighed to test
location eccentricity, and the weigh factors are unpublished, we
applied the NPA criterion to the eccentricity-uncorrected average
sensitivity of all test locations (mean sensitivity).
Calculations and statistical analyses were performed using SPSS
Statistics 18.0 (SPSS Inc., Chicago, IL); the ANOVA was
performed using MrF (http://psy.otago.ac.nz/miller/).
Results
Table 2 shows the patient characteristics. Two-hundred-twenty-
one patients were included of which 53 performed at least eight
tests and had at least one test location showing a ,0 dB sensitivity
on four consecutive baseline tests. The average follow-up durations
were 6.4 and 6.9 years, respectively, with median MD values at
baseline of 27.0 and 214.7 dB.
Figure 1 shows the blindness persistence characteristics as a
function of the number of consecutive baseline sensitivities below
,0, ,5, ,10 and ,20 dB. The boxplots visualize the between-
patient variability; the corresponding mean within-patient stan-
dard deviations were, following the sequence of Fig. 1 from left to
right, 25, 23, 21, 20, 16, 15, 13, 12, 14, 10, 9, 10, 13, 9, 9 and 8%.
If the number of consecutive baseline tests on which a test location
was blind increased, the probability of being blind during follow-
up increased. The increase in blindness persistence appeared to
saturate at three consecutive baseline sensitivities below the
concerning value. Blindness persistence appeared to be highest
for ,10 and ,20 dB and lowest for ,0 dB. Table 3 shows that
blindness persistence depended significantly on both the number
of consecutive tests showing blindness in a test location (P,0.001)
and the definition of blindness (P,0.001). Figure 2 presents the
corresponding mean sensitivity as recorded during the four follow-
up tests in the presumed blind test locations.
Figure 3 illustrates the spatial distributions of test locations that
met the requirement of three consecutive sensitivities of ,0 (A),
,10 (B) and ,20 (C) dB, and that were ‘out of range’ according to
the GPA (D), as a function of baseline MD. The number of blind
test locations increased monotonically with MD for all criteria of
blindness except for GPA; for GPA the number of test location
flagged as ‘out of range’ decreased again with advanced glaucoma.
As a consequence, significantly less sensitivities were ‘out of range’
according to GPA compared to blindness at ,0 dB for baseline
MD values below 225 dB (P,0.001), while the opposite was the
case for all other strata (P,0.001). For the three consecutive ,0
dB criterion (Figure 3A), the median (interquartile range)
percentages of blind test locations were 0(0–0), 0(0–2), 4(0–9),
17(8–27), 27(20–40) and 60(50–70)% for the six MD strata.
Figure 4 presents a scatter plot showing the percentages of blind
test locations according to the three consecutive ,0 dB criterion
for all test locations of the 30–2 grid versus a subset of 12 test
locations located within the 10–2 grid. For the subset, the median
(interquartile range) percentages of blind test locations were 0(0–
0), 0(0–2), 6(4–11), 8(4–18), 23(13–48) and 50(40–70)% for the six
MD strata. These percentages were similar to the corresponding
percentages for the 30–2 grid (listed above) for all six MD strata
(P= 0.32, 0.34, 0.11, 0.44, 0.17 and 0.23, respectively).
Figure 5 shows Venn diagrams indicating the number of eyes
with at least possible progression at the end of the follow-up
according to NPA versus NPA after removing all test locations that
Figure 4. Percentage of blind test locations according to the three consecutive,0 dB criterion for all test locations within the 30–2
grid (x-axis) versus a subset of test locations within the 10–2 grid (y-axis). Symbols indicate stratification according to baseline mean
deviation (MD) in six strata, being up to -5 dB, from -5 to -10 dB, -10 to -15 dB, -15 to -20 dB, -20 to -25 dB en beyond -25 dB. Noise with a standard
deviation of 1% was added in order to avoid overlapping data points.
doi:10.1371/journal.pone.0041211.g004
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were blind on the first three tests (NPA-RONI, where RONI is
regions of no interest) for four different definitions of blindness:
,0, ,5, ,10 and ,20 dB. There was no significant difference
between the classifications by both approaches (P = 0.25, P= 1.0,
P = 1.0 and P= 0.26 for ,0, ,5, ,10 and ,20 dB, respectively).
Similar findings were done in the subset of 53 eyes (P = 0.25,
P= 1.0, P= 1.0 and P= 0.75 for ,0, ,5, ,10 and ,20 dB,
respectively).
Discussion
Test locations with a sensitivity below a certain value on three
consecutive occasions are unlikely to show a substantially higher
sensitivity later on. Hence, if the concerning value corresponds to
the maximum stimulus intensity of the perimeter used, these test
locations do no longer contribute to progression detection.
Omitting these locations from future tests will result in time
saving without hampering progression detection. Obviously, the
number of blind test locations (and thus the potential time saving)
increases with increasing disease severity. Interestingly, the
percentages of blind test locations appeared to be similar for 30–
2 and 10–2 grids for all disease stages.
With the introduction of the SITA strategies in the late ninety’s
of the previous century, the examination time of standard
automated perimetry decreased substantially [14]. Unfortunately,
this advantage over the full-threshold strategy is largely lost in
severe glaucoma. Older Octopus strategies and the German
Adaptive Threshold Estimation (GATE) algorithm overcome this
increase in test time by using information from previous test results
to determine more appropriate starting values for the stair-case
procedure [6,7]. We would suggest a further step by entirely
omitting test locations that were shown to be blind at earlier
occasions (‘regions of no interest’). This enables more time saving
but obviously limits the application of our approach to irreversible
eye diseases. Leaving out test locations may seem crude, but this is
what is actually done by clinicians who exchange the default 30–2
grid by a 10–2 grid in advanced glaucoma and by clinicians who
rely on GPA for progression detection. Interestingly, GPA ignores
even more test locations than we propose to do with our ‘regions of
no interest’ approach (see below and Results section). As GPA
leaves them out in the analysis phase only, however, no time
saving is obtained.
The time gained by the suggested approach should be
interpreted and weighed correctly. Obviously, if the time saving
is compared to the total time spent in the hospital, the saving is
negligible. However, not testing blind test locations refrains a
patient with moderate or advanced glaucoma from long time
periods in which he or she does not observe any stimulus but has to
stay alert nonetheless. This should increase concentration, thus
increasing the reliability of the test result. Second, long time
periods without any visible stimulus increase patient frustration by
emphasizing not seeing things. Third, the saved time can be used
to study the remaining parts of the visual field in more detail
without additional visits or costs. This can be done by either
adding test locations or determining thresholds more accurately.
Obviously, to allow for a reliable progression detection throughout
the follow-up, only the test locations belonging to the original grid
should contribute to the MD. The added test locations, however,
may be analyzed separately and may yield important information
[9,10].
A caveat of incorporating our regions-of-no-interest approach is
that it may cause propagation of blindness through the visual field
if applied to strategies that use some form of spatial smoothing
(that is, do not determine a formal threshold in all individual test
locations) in order to reduce test time (as possibly occurs in SITA).
This will not occur in strategies that use neighboring sensitivities
only for estimating a starting value for determining a threshold.
The classical picture of glaucoma deterioration is the develop-
ment of visual field defects initially in the periphery, leaving vision
Figure 5. Venn diagrams showing progression according
Nonparametric Progression Analysis (NPA) versus NPA after
removing all test locations that were blind on the first three
tests (NPA-RONI, where RONI is regions of no interest). Four
different definitions of blindness were used: ,0, ,5, ,10 and ,20 dB.
Results for all 221 subjects with results for the subset of 53 subjects
between brackets.
doi:10.1371/journal.pone.0041211.g005
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unaltered centrally until the latest stages of the disease. Albeit this
picture has been challenged recently [9,10], the clinical translation
of this picture is starting with 30–2 testing with a transition to 10–2
somewhere along the line - the easiest way to get rid of
unresponsive parts of the visual field in advanced disease. One
of the aims of this study was to develop a clinically useful guideline,
that is, an MD cut-off value, for preferring 10–2 testing over 30–2
testing in advanced glaucoma. Interestingly, no such an MD value
appeared to exist – the median percentage of blind test locations
was essentially identical for 30–2 and 10–2 grids for all disease
stages. With a closer look at our data, this corresponded to the
three clinically well known patterns of visual field loss in severe
glaucoma: (1) a central island without a peripheral (temporal)
island, (2) a temporal island without a central island, and (3) both a
central and a temporal island. This is also visible in Figure 4.
Hence, in many patients a transition from 30–2 to 10–2 testing will
never become an meaningful change. It is important to realize that
we did not actually measure a 10–2 grid – a form of high spatial
resolution perimetry [15,16] - but analyzed a subset of 30–2 test
locations laying within the 10–2 area. Here, the assumption is that
this can be considered a representative (unbiased) sample. Also,
inclusion of a patient in this study implied the presence of 30–2
fields. This might have induced a selection bias, as patients with
only a central island might be underrepresented because they were
at baseline already monitored with 10–2 testing – and thus
excluded. This is unlikely, however, as at the baseline of the GLGS
Goldmann perimetry and not 10–2 testing was the default escape
in advanced glaucoma [11] – suggesting an underrepresentation of
temporal islands rather than of central islands in this study. To
conclude, the transition from 30–2 to 10–2 testing should be
individualized and the advantage of a more detailed monitoring of
a central island should be weighed against the need of building a
new baseline and the loss of monitoring of any peripheral island.
After all, it is not unlikely that progression in the periphery predicts
future central loss.
Figure 3A-C actually depicts the ‘‘average’’ glaucoma progres-
sion pattern. Not unexpectedly, the glaucomatous deterioration
starts nasal-superiorly. In agreement with the findings discussed in
the paragraph above, both a central and a temporal island
survived until the last MD stratum. With GPA, the number of test
locations with a cross (indicating that the software ignores these
location for progression detection) increases with disease progres-
sion up to an MD of about -20 dB but decreases beyond that point
(Figure 3D). Although this pattern is identical to what is observed
in the pattern deviation plot and is in agreement with the idea that
GPA is based on pattern deviation analysis [17], it might mislead
the clinician as it suggests erroneously that test locations that are
actually blind are still monitored.
The absence of a response to the maximum stimulus intensity is
not identical to blindness. The dynamic range of the perimeter can
be increased by replacing stimulus size III by size V. Interestingly,
this appears to reduce the test-retest variability [18–20]. Until
now, however, the time-saving SITA strategy is not available for
size V. Within a given stimulus size, it is not self-evidently
beneficial to increase the dynamic range by increasing the
maximum stimulus intensity. Although the well-known pointwise
test-retest variability plot (for our data shown in Figure 6) suggests
a reduced variability close to the maximum stimulus intensity, this
is merely a floor effect. If we look in an alternative way to the same
data (Figure 1), it might be the case that the extended dynamic
range as used in HFA compared to Octopus and Oculus
corresponds to a reduced reproducibility of blindness (Table 3).
This is in line with the idea that a high test-retest variability is
related to ganglion cell saturation [21], but requires further study.
Figure 6. Pointwise test-retest variability. Data presented in strata of 2 dB, except for,0 dB which was set to -1.5 dB in one box. Boxplots show
median, interquartile range, and 5th, 10th, 90th and 95th percentiles.
doi:10.1371/journal.pone.0041211.g006
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The exclusion of test locations with a sensitivity of ,0, ,5 or
,10 dB at baseline did not affect progression detection with NPA
(Figure 5). Only for ,20 dB some difference (albeit statistically not
significant) appeared to occur. Here, progression according to
NPA but not according to NPA-RONI might reflect deepening of
existing defects (that is, test locations with a sensitivity already ,20
dB at baseline); progression according to NPA-RONI but not
according to NPA might be caused by a reduced variability in the
calculated mean sensitivity for the RONI approach, which results
in an increase in NPA sensitivity [22,23]. These observations are
in line with the findings described in the previous paragraph. It
might be possible that other progression detection algorithms
would be affected differently. This requires further study.
Originally, the SITA fast strategy, as used in the GLGS, was
considered a time-saving improvement of the SITA standard
strategy and for that reason we adopted it in our study designed in
1999. Later it became clear that the strategies performed slightly
different. Two studies reported a slightly higher sensitivity for
SITA standard in comparison with SITA fast [24,25]; one study
reported a higher sensitivity for SITA fast [26]. These differences –
if any – are not relevant to the current study. More relevant to the
current study is the finding that SITA fast seems to have a higher
test-retest variability in areas with a reduced sensitivity in
comparison with SITA standard [27]. This tentatively suggests
that blindness reproducibility might be better in SITA standard
and thus our criterion – three consecutive ,0 dB readings –
should be applicable to SITA standard as well.
In conclusion, current perimetric strategies share the inconve-
nient property that test-time increases in advanced glaucoma,
while a smaller residual visual field has to be tested. A more clever
customizing to what has to be tested than a default change to 10–2
testing should allow for an improved and uninterrupted long-term
monitoring of glaucoma patients with standard automated
perimetry.
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